
Superpower peptides available for pre-order. Get first access.

Peptide science
Is pinealon safe?
Human safety of pinealon is unknown, with no Phase 1 trial published. See what animal data show, what is unstudied, and the risks of unregulated products.
Quick answer
Pinealon's safety in people is unknown, because no Phase 1 trial has been published and no clinical trial is registered. The evidence comes mainly from limited cell and animal studies in Russian labs and a few small human reports, which often paired pinealon with a second peptide, vesugen. Pinealon is not FDA approved, and unregulated pinealon products carry added identity and purity risks.
- Published
- November 12, 2026
- Last updated
- November 12, 2026
Pinealon's safety in people is still unknown
Whether pinealon is safe for people is unknown, because no Phase 1 study has been published. As of November 2026, no clinical trial of pinealon is registered1. Phase 1 measures how much of a drug people can tolerate2 and what its acute side effects are. Pinealon, the tripeptide Glu-Asp-Arg also called the EDR peptide, has been studied mainly in preclinical research3 and small human reports.
What pinealon studies report about safety and side effects
Pinealon studies in cells and animals were designed to measure protective effects, so they reveal little about pinealon side effects. Many unapproved peptides look promising in animals while rigorous human safety data remain scarce4.
In cultured cells, pinealon lowered free-radical levels5 and necrotic cell death. Alzheimer's model mice given pinealon daily for two months6 showed brain-cell changes, with no tolerability measures reported. Old rats given pinealon before blocked brain blood flow survived better, but their motor and motivational behavior declined. Those rats also showed moderately higher activity of caspase-37, a cell-death enzyme.
Human data come from a few small Russian reports, often pairing pinealon with a second peptide, vesugen. In 110 people, one report rated the pair "the most safe" of several anti-aging methods8 it compared. Another, in 32 people with a chronic brain disorder, reported increased oxidative (cell-stressing) activity and fewer blood-forming stem cells9.
All of these pinealon studies come from Russian groups, several tied to St. Petersburg's Institute of Bioregulation and Gerontology. Neither of the two human reports describes a control group, and both report their safety findings for pinealon and vesugen together.
Key questions about pinealon's safety remain unanswered
The basic safety facts that early drug development is meant to establish10 have not been documented for pinealon in people. Open questions include:
- How the body absorbs, distributes, breaks down, and clears pinealon
- Which side effects occur, and how often
- Whether pinealon interacts with prescription drugs, supplements, or other peptides
- Long-term effects, a gap shared by unapproved peptides that lack long-term safety data11
- How pinealon affects older adults and people with chronic medical conditions
These unknowns concern pinealon itself, while unregulated products raise a separate question about their contents.
Unregulated pinealon products add identity and purity risks
Pinealon sold online comes from outside the regulated drug supply, so buyers cannot confirm its identity, purity, potency, or sterility12. Lab analyses of seized illegal peptide products in general have found peptides still in preclinical development13. Falsified peptide drugs more broadly have carried the wrong active ingredient14, the wrong dose, or none at all.
In falsified peptides bought from suspected illegal online pharmacies, purity ranged from 5% to 75%15 for one peptide group. Some samples also carried arsenic or lead, and several had levels up to 10 times the safety limit for injectable drugs.
Other research peptides sold for brain function have turned up in seized pharmaceutical preparations16. US health officials have described research-use-only peptides from foreign manufacturers as a safety risk to US patients17. Some people also have extra reasons for caution with pinealon itself.
Who has extra reason for caution with pinealon
Pinealon has no controlled safety data in any group of people, and some groups have added reasons for caution:
- People with a brain or nerve tumor: a peptide matching pinealon's sequence stimulated cell growth18 in rat skin-tissue cultures, and its effect on tumors is unstudied.
- People who are pregnant or breastfeeding: drugs lacking pregnancy and lactation safety data may carry risks for unborn or newborn babies19. Pinealon's pregnancy data come from rat disease models, such as pregnant rats with induced high homocysteine20, built to test protection rather than reproductive safety.
- People taking medications that raise serotonin: in aging brain-cortex cell cultures, pinealon raised serotonin expression21, though pinealon's serotonin effect has not been shown in people. Combining serotonin-raising drugs22 can cause serotonin syndrome, a potentially life-threatening reaction.
- Competitive athletes: as of the 2026 WADA Prohibited List, pinealon may fall under the S0 category banning non-approved substances at all times23, so athletes subject to anti-doping testing should check with their governing body.
These cautions rest on lab findings and sport rules rather than harm reported in people.
Where can I learn about peptides?
Pinealon safety claims are easier to weigh once you know what each study set out to measure. Superpower’s peptide library is written and fact-checked by a team of health journalists and licensed clinicians.
For broader context, the science behind peptides traces how a peptide moves from cell cultures toward human testing.
IMPORTANT SAFETY INFORMATION
Pinealon (EDR peptide; Glu-Asp-Arg) is not FDA-approved for any medical use. No Phase 1 human safety study has been published, and no clinical trial of pinealon is registered. Its side effect profile, pharmacokinetics, drug interactions, appropriate dosing, and long-term effects in humans have not been established.
Published pinealon research consists of cell and animal studies and a few small human reports from Russian research groups. The human reports describe no control group and report their findings for pinealon and vesugen together, so they cannot be used to characterize pinealon's risk in people.
Pinealon should not be used by anyone outside an IRB-approved clinical research study. No approved label exists, so no formal contraindications exist. Populations of particular theoretical concern include: people with a brain or nerve tumor (effects on cell growth have not been studied in tumors); people who are pregnant or breastfeeding (no human pregnancy or lactation data exist); and people taking medications that raise serotonin (interactions have not been studied). These are illustrative concerns, not a contraindication checklist.
Products sold online as pinealon are unregulated. They are not subject to FDA oversight, cGMP manufacturing standards, or identity, purity, potency, and sterility verification. Low purity, wrong or missing active ingredients, and heavy-metal contamination are documented risks of unregulated and falsified peptide products.
The World Anti-Doping Agency's Prohibited List class S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use and is prohibited at all times. Competitive athletes subject to anti-doping testing should confirm pinealon's status with their governing body.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Pinealon. Pinealon is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.